Öz
Amaç: Toxoplasma gondii dünya üzerinde pek çok canlı türünü enfekte eden ve insanlarda özellikle
immun sistemi baskılanmış hastalarda ölümle sonuçlanabilecek klinik tablolara
yol açan bir protozoondur. Kanser hastalarında uygulanan kemoterapi ve
radyoterapi hem hücresel hem de humoral immun sistemi bozarak latent durumda
bulunan T. gondii' nin
reaktivasyonuna yol açmaktadır. Çalışmamızda, Sivas Cumhuriyet Üniversitesi
Sağlık Hizmetleri Uygulama ve Araştırma Hastanesine başvuran ve kanser tedavisi
gören hastalarda T. gondii
seroprevalansının ELISA yöntemi ile belirlenmesi amaçlanmıştır.
Yöntem: Çalışma, Cumhuriyet Üniversitesi Sağlık
Hizmetleri Uygulama ve Araştırma Hastanesi Radyasyon Onkolojisi Polikliniğine
başvuran, 18-80 yaş aralığında hastalar üzerinde yapılmış ve örneklem sayısı,
100 kemoterapi alan kanser hastası ve 100 sağlıklı kontrol grubu kişiden
oluşturulmuştur. Bu kişilerden alınan kan örneklerinde Toxoplasma IgG ve IgM antikorları ELISA yöntemi ile
araştırılmıştır.
Bulgular: Çalışmamızda,
Cumhuriyet Üniversitesi Sağlık Hizmetleri Uygulama ve Araştırma Hastanesinde
kemoterapi alan 100 kanserli hastanın 60’ında (%60.0) IgG pozitifliği saptanmış
olup, kontrol grubunun 27’sinde (%27.0) pozitiflik görülmüştür. Aralarındaki
farklılık önemli bulunmuştur. Çalışmaya alınan kanser hastaları başlıca;
akciğer, meme, mide, kolon, over kanserlerinden oluşmaktadır. Kanserli
hastalarla kontrol grubunun her ikisinde de bir kişide (%1.0) IgM pozitifliği
saptanmış olup gruplar arası farklılık önemsiz bulunmuştur.
Sonuç: Bağışıklık
sistemi baskılanmış kanser hastalarında, bağışıklık sistemi normal olan bireylerde
daha nadir görülen toksoplazmoz gibi fırsatçı infeksiyonlara daha sık
rastlanmaktadır. Bu kişiler hem enfeksiyonlara daha yatkındır hem de daha önce
geçirilmiş olan toksoplazmozun reaktivasyon riski bu hastalarda daha yüksektir.
Bu nedenle; bu hastaların belirli periyotlarla Toxoplasma açısından
değerlendirilmeleri uygun olacaktır.
Anahtar Kelimeler
Toxoplasma gondii anti-Toxoplasma IgG anti-Toxoplasma IgM seroprevalans kanser
Kaynakça
- 1. Saygı G. Parasitic diseases and parasites, Toxoplasmosis 2009; 144-53.
- 2. Beaman MH, Mc Cabe RE, Wong S, et al.Toxoplasma gondii mandell douglass and bennett’s principles and practice of infectious diseases. 4. Edit, Churcill, Livingstone, New York. 1995; 2455-75.
- 3. Tenter AM, Heckeroth AR, Weiss LM. Toxoplasma gondii: from animals to humans. Int J Parasitol 2000;30:1217-1258.
- 4. Güler S. Investigation of Anti-Toxoplasma gondiiantibodies in the sheep slaughtered in Niğde’s laughterhouse using the ELISA test: Science institute, Niğde University. 2011.
- 5. Sahin I, Onbasi K, Sahin H, et al. Frequency of anti-Toxoplasma antibodies in patients with chronic renal failure undergoing hemodialysis in Van region. Official J Turkish Society of Nephrology 2002; 2: 22-6.
- 6. Boluk S, Ozyurt BC, Girginkardesler N, et al. Evaluation of serological results of patients with suspected toxoplasmosis admitted to the medical parasitology laboratory of celal bayar university hospital between 2006-2010. Turkish j Parasitol 2012; 36: 137-141.
- 7. Cevizci S, Bakar C. Toxoplasma gondii with public health’s perspective. Turkish J Public Health 2013; 11: 45.
- 8. Polat M, Kilic E, Yazar S, et al. Assessment of advanced positive oxidation product levels in Toxoplasma gondii positive individuals. Erciyes University, J Health Sci 2012; 21: 200-4.
- 9. Gulesci E, Oktun M. Investigation of anti-toxoplasma antibodies in patients with hematological malignancy Turkish J Parasitol 2005; 29: 85-8.
- 10. Khalil H, Makled M, Azab M, et al. Opportunistic parasitic infections in immunocompromised hosts. J Egyptian Soc Parasitol 1991; 21: 657-68.
- 11. Gungor C, Ataoglu H, Altintas K. Investigation of the Toxoplasma IgM, IgG and Sabin-Feldman antibodies in acute leukemia patients taking immunosuppressive drugs. Turkish J Parasitol 1993; 17: 21-6.
- 12. Huang H, Yan F, Li C, et al. Detection of Toxoplasma infection in women with gynaecologic neoplasms using ELISA. Zhongguo ji sheng chong xue yu ji sheng chong bing za zhi= Chinese J Parasitol & Parasitic Diseases 1999; 18: 165-66.
- 13. Wang B, Pan X, Yin Y, et al. Investigation of anti-Toxoplasma gondii antibodies in immunodeficient patients. Zhongguo ji sheng chong xue yu ji sheng chong bing za zhi= Chinese J Parasitol & Parasitic Diseases 1999; 18:224-226.
- 14. Hokelek M, Uyar Y, Gunaydin M, et al. Investigation of Toxoplasma antibodies in cancer patients receiving chemotherapy. Turkish J Parasitol 2001; 25: 217-9.
- 15. Ciftci I.H, Bozkurt H, Guducuoglu H, et al. Toxoplasmosis seroprevalence in cancer patients in Van region. Van Med J 2003; 10-15.
- 16. Yazar S, Yaman O, Eser B, et al. Investigation of anti-Toxoplasma gondii antibodies in patients with neoplasia. J Med Microbiol 2004; 53: 1183-6.
- 17. Shin DW, Cha DY, Hua QJ, et al. Seroprevalence of Toxoplasma gondii infection and characteristics of seropositive patients in general hospitals in Daejeon, Korea. Korean J Parasitol 2009; 47: 125-30.
- 18. Vittecoq M, Elguero E, Lafferty KD, et al. Brain cancer mortality rates increase with Toxoplasma gondii seroprevalence in France. Infection Genetics and Evolution 2012; 12: 496-8.
- 19. Deveci H, Kobak S. Toxoplasma uveitis in the case with ankylosing spondylitis. Turkish J Parasitol 2013; 37: 216-8.
- 20. Ahmadpour E, Daryani A, Sharif M, et al. Toxoplasmosis in immunocompromised patients in Iran: a systematic review and meta-analysis. J Infection in Developing Countries 2014; 8: 1503-10.
- 21. Cong W, Liu G.H, Meng Q.F, et al. Toxoplasma gondii infection in cancer patients: prevalence, risk factors, genotypes and association with clinical diagnosis. Cancer letters 2015; 359: 307-13.
- 22. Lu N, Liu C, Wang J, et al. Toxoplasmosis complicating lung cancer: a case report. Int Med Case Reports J 2015; 8: 37-42.
Öz
Objective: Toxoplasma gondii is a
protozoon infecting many living species in the world and causing clinical
pictures that can end with death in humans, especially in patients with blunted
immune system. Chemotherapy and radiotherapy administrations in cancer patients
cause the reactivation of latent T. gondii by impairing both cellular and
humoral immune system. The purpose of this study is to determine the
seroprevalences of anti-Toxoplasma IgG and IgM antibodies in patients who have
applied to and received cancer treatment in the Health Services Research and
Application Hospital of Cumhuriyet University in Sivas
Method: The study was conducted on the
patients aged between 18-80, who applied to the Radiation Oncology Polyclinic
in the Health Services Research and Application Hospital of Cumhuriyet
University and the sample consisted of 100 cancer patients receiving chemotherapy
and 100 healthy people in the control group. Anti-Toxoplasma IgG and
anti-Toxoplasma IgM antibodies were analyzed with the ELISA method in the blood
samples taken from this peoples.
Results: In our study, IgG positivity was
determined in 60 (60.0%) of the 100 cancer patients receiving chemotherapy in
the Health Services Research and Application Hospital of Cumhuriyet University
and 27 (27.0%) of the control group. The difference between the groups was
found to be significant. Cancer patients included in the study consisted of
especially lung cancer, breast cancer, stomach cancer, colon cancer and ovarian
cancer patients. Evaluating the professional statuses of the 100 cancer
patients included in the study, 40 of the patients were determined to be housewives
and 36 patients were determined to be retired. The habit of feeding cats was
determined to be 30.9% in the same patient group with the survey conducted.
Furthermore, 66% of the patients stated that they consumed raw meat. It was
determined that none of the patients received an organ transplant. IgM
positivity (1.0%) was determined in one individual in both the cancer patients
and the control group, and the difference between the groups was found to be
insignificant.
Conclusions: Opportunistic infections like
toxoplasmosis are more frequent in cancer patients with the blunted immune
system compared to individuals with the normal immune systems. These
individuals are more prone to infections and the risk of the reactivation of
toxoplasmosis experienced before is higher in these patients. Therefore, it
will be appropriate for these patients to be periodically evaluated in terms of
Toxoplasma.
Anahtar Kelimeler
Toxoplasma gondii anti-Toxoplasma IgG anti-Toxoplasma IgM seroprevalance cancer
Kaynakça
- 1. Saygı G. Parasitic diseases and parasites, Toxoplasmosis 2009; 144-53.
- 2. Beaman MH, Mc Cabe RE, Wong S, et al.Toxoplasma gondii mandell douglass and bennett’s principles and practice of infectious diseases. 4. Edit, Churcill, Livingstone, New York. 1995; 2455-75.
- 3. Tenter AM, Heckeroth AR, Weiss LM. Toxoplasma gondii: from animals to humans. Int J Parasitol 2000;30:1217-1258.
- 4. Güler S. Investigation of Anti-Toxoplasma gondiiantibodies in the sheep slaughtered in Niğde’s laughterhouse using the ELISA test: Science institute, Niğde University. 2011.
- 5. Sahin I, Onbasi K, Sahin H, et al. Frequency of anti-Toxoplasma antibodies in patients with chronic renal failure undergoing hemodialysis in Van region. Official J Turkish Society of Nephrology 2002; 2: 22-6.
- 6. Boluk S, Ozyurt BC, Girginkardesler N, et al. Evaluation of serological results of patients with suspected toxoplasmosis admitted to the medical parasitology laboratory of celal bayar university hospital between 2006-2010. Turkish j Parasitol 2012; 36: 137-141.
- 7. Cevizci S, Bakar C. Toxoplasma gondii with public health’s perspective. Turkish J Public Health 2013; 11: 45.
- 8. Polat M, Kilic E, Yazar S, et al. Assessment of advanced positive oxidation product levels in Toxoplasma gondii positive individuals. Erciyes University, J Health Sci 2012; 21: 200-4.
- 9. Gulesci E, Oktun M. Investigation of anti-toxoplasma antibodies in patients with hematological malignancy Turkish J Parasitol 2005; 29: 85-8.
- 10. Khalil H, Makled M, Azab M, et al. Opportunistic parasitic infections in immunocompromised hosts. J Egyptian Soc Parasitol 1991; 21: 657-68.
- 11. Gungor C, Ataoglu H, Altintas K. Investigation of the Toxoplasma IgM, IgG and Sabin-Feldman antibodies in acute leukemia patients taking immunosuppressive drugs. Turkish J Parasitol 1993; 17: 21-6.
- 12. Huang H, Yan F, Li C, et al. Detection of Toxoplasma infection in women with gynaecologic neoplasms using ELISA. Zhongguo ji sheng chong xue yu ji sheng chong bing za zhi= Chinese J Parasitol & Parasitic Diseases 1999; 18: 165-66.
- 13. Wang B, Pan X, Yin Y, et al. Investigation of anti-Toxoplasma gondii antibodies in immunodeficient patients. Zhongguo ji sheng chong xue yu ji sheng chong bing za zhi= Chinese J Parasitol & Parasitic Diseases 1999; 18:224-226.
- 14. Hokelek M, Uyar Y, Gunaydin M, et al. Investigation of Toxoplasma antibodies in cancer patients receiving chemotherapy. Turkish J Parasitol 2001; 25: 217-9.
- 15. Ciftci I.H, Bozkurt H, Guducuoglu H, et al. Toxoplasmosis seroprevalence in cancer patients in Van region. Van Med J 2003; 10-15.
- 16. Yazar S, Yaman O, Eser B, et al. Investigation of anti-Toxoplasma gondii antibodies in patients with neoplasia. J Med Microbiol 2004; 53: 1183-6.
- 17. Shin DW, Cha DY, Hua QJ, et al. Seroprevalence of Toxoplasma gondii infection and characteristics of seropositive patients in general hospitals in Daejeon, Korea. Korean J Parasitol 2009; 47: 125-30.
- 18. Vittecoq M, Elguero E, Lafferty KD, et al. Brain cancer mortality rates increase with Toxoplasma gondii seroprevalence in France. Infection Genetics and Evolution 2012; 12: 496-8.
- 19. Deveci H, Kobak S. Toxoplasma uveitis in the case with ankylosing spondylitis. Turkish J Parasitol 2013; 37: 216-8.
- 20. Ahmadpour E, Daryani A, Sharif M, et al. Toxoplasmosis in immunocompromised patients in Iran: a systematic review and meta-analysis. J Infection in Developing Countries 2014; 8: 1503-10.
- 21. Cong W, Liu G.H, Meng Q.F, et al. Toxoplasma gondii infection in cancer patients: prevalence, risk factors, genotypes and association with clinical diagnosis. Cancer letters 2015; 359: 307-13.
- 22. Lu N, Liu C, Wang J, et al. Toxoplasmosis complicating lung cancer: a case report. Int Med Case Reports J 2015; 8: 37-42.
Ayrıntılar
| Birincil Dil | İngilizce |
|---|---|
| Konular | Sağlık Kurumları Yönetimi |
| Bölüm | Basic Science Research Makaleler |
| Yazarlar | |
| Yayımlanma Tarihi | 20 Mart 2018 |
| Kabul Tarihi | 26 Şubat 2018 |
| Yayımlandığı Sayı | Yıl 2018Cilt: 40 Sayı: 1 |